Janney Capital Management LLC Invests $384,000 in Structure Therapeutics Inc. Sponsored ADR $GPCR

Janney Capital Management LLC bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the third quarter, Holdings Channel reports. The fund bought 13,718 shares of the company’s stock, valued at approximately $384,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pacific Heights Asset Management LLC acquired a new position in Structure Therapeutics during the second quarter worth $9,540,000. Orbimed Advisors LLC increased its stake in shares of Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after purchasing an additional 397,272 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth about $3,480,000. Aberdeen Group plc lifted its stake in Structure Therapeutics by 61.4% in the 2nd quarter. Aberdeen Group plc now owns 401,624 shares of the company’s stock valued at $8,330,000 after buying an additional 152,725 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Structure Therapeutics by 474.9% in the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after buying an additional 145,434 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

GPCR stock opened at $77.92 on Wednesday. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $13.22 and a 1 year high of $94.90. The firm has a market capitalization of $4.73 billion, a PE ratio of -63.87 and a beta of -2.05. The business has a 50 day simple moving average of $52.12 and a 200-day simple moving average of $32.86.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on GPCR shares. Citizens Jmp increased their target price on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a report on Friday, December 12th. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright lifted their target price on shares of Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and an average price target of $99.11.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.